Ekzom Nedir?
November 14, 2025
What is a Carrier Screening Test?
November 14, 2025Ekzom Nedir?
November 14, 2025What is a Carrier Screening Test?
November 14, 2025
What Is the NIPT Test?
NIPT (Non-Invasive Prenatal Test) is a safe screening method that evaluates the chromosomal health of the baby by analyzing cell-free fetal DNA found in the mother’s blood. RapidNIPT is Genoks’ NIPT service brand developed with advanced technological infrastructure, offering high accuracy, fast results, and comprehensive prenatal screening within a single test.
NIPT Prenatal Screening Test
Reliable prenatal assessment at an early stage. Identifying chromosomal abnormalities during pregnancy is a critical process; however, invasive tests may not always be appropriate. Thanks to modern cfDNA analysis technology, NIPT enables highly accurate assessment starting from the 10th week of pregnancy.
Comprehensive chromosomal analysis from a single blood sample. RapidNIPT analyzes cell-free fetal DNA (cfDNA) circulating in maternal blood to provide comprehensive risk assessment for Trisomy 21 (Down Syndrome), Trisomy 18, Trisomy 13, and other chromosomal variations. All analyses are performed in Genoks’ advanced automated laboratory.
High accuracy, low uncertainty. cfDNA-based analyses are non-invasive and help reduce unnecessary risks associated with invasive procedures. RapidNIPT evaluates fetal genetic signals with high sensitivity using advanced molecular techniques.
A completely safe process for both mother and baby.
The test is performed through a routine blood draw and poses no risk to either the mother or the baby. With fast turnaround times and expert medical genetic evaluation, it supports informed decision-making throughout pregnancy.
A Safe and Comprehensive RapidNIPT Test for Your Pregnancy
A completely risk-free non-invasive prenatal screening test for both mother and baby, based on whole-genome next-generation sequencing (NGS). It evaluates more than 90 chromosomal conditions with an accuracy rate exceeding 99%.
- Genetic Evaluation Method Chromosomes are analyzed for numerical abnormalities using cell-free DNA data obtained from maternal blood.
- Non-Invasive Approach The analysis is conducted solely on a maternal blood sample, with no intervention in the pregnancy.
- International Quality Framework Laboratory processes are structured in compliance with EMQN external quality assessment programs and relevant ISO standards.
- Structured Reporting Genetic evaluation results are presented in a standardized report format designed to support clinical decision-making.
Parameters Evaluated with RapidNIPT
Autosomal Aneuploidies
| Monosomy 1 / Trisomy 1 | Monosomy 12 / Trisomy 12 |
| Monosomy 2 / Trisomy 2 | Monosomy 13 / Trisomy 13 (Patau Syndrome) |
| Monosomy 3 / Trisomy 3 | Monosomy 14 / Trisomy 14 |
| Monosomy 4 / Trisomy 4 | Monosomy 15 / Trisomy 15 |
| Monosomy 5 / Trisomy 5 | Monosomy 16 / Trisomy 16 |
| Monosomy 6 / Trisomy 6 | Monosomy 17 / Trisomy 17 |
| Monosomy 7 / Trisomy 7 | Monosomy 18 / Trisomy 18 (Edwards Syndrome) |
| Monosomy 8 / Trisomy 8 | Monosomy 19 / Trisomy 19 |
| Monosomy 9 / Trisomy 9 | Monosomy 20 / Trisomy 20 |
| Monosomy 10 / Trisomy 10 | Monosomy 21 / Trisomy 21 (Down Syndrome) |
| Monosomy 11 / Trisomy 11 | Monosomy 22 / Trisomy 22 |
Sex Chromosome Aneuploidies
Deletion / Duplication Syndromes (for deletions and duplications ≥ 7 Mb)
| 11q11-q13.3 Duplication Syndrome | 1p36 Deletion Syndrome |
| 12q14 Deletion Syndrome | 1q41-q42 Deletion Syndrome |
| 14q11-q22 Deletion Syndrome | Glass Syndrome (2q33.1) |
| 15q26 Overgrowth Syndrome | 5q21.1-q31.2 Deletion Syndrome |
| 16p11.2-p12.2 Deletion Syndrome | 8p23.1 Deletion Syndrome |
| 16p11.2-p12.2 Duplication Syndrome | 8p23.1 Duplication Syndrome |
| 17q21.31 Deletion Syndrome | Alpha Thalassemia / Intellectual Disability Syndrome (16p13.3) |
| 17q21.31 Duplication Syndrome | Angelman / Prader-Willi Syndrome (15q11-q13) |
| Aniridia II & WAGR Syndrome (11p13) | Holoprosencephaly Type 4 (18p11.31) |
| Bannayan-Riley-Ruvalcaba Syndrome (10q23.31) | Holoprosencephaly Type 6 (2q37.1-q37.3) |
| Cat-Eye Syndrome (22q11.21) | Jacobsen Syndrome (11q24-q25) |
| Cri du Chat Syndrome (5p15.2) | Smith-Magenis Syndrome (17p11.2) |
| Condition | Sensitivity (%) |
|---|---|
| Trisomy 21 | >99 |
| Trisomy 18 | >99 |
| Trisomy 13 | >99 |
| Rare autosomal aneuploidies | 96.4 |
| Deletion/Duplication ≥ 7Mb | 74.1 |
| Method | |
|---|---|
| RapidNIPT® utilizes Illumina VeriSeq NIPT Solution v2 technology. The analysis of cfDNA (cell-free DNA) isolated from maternal blood is performed using whole-genome next-generation sequencing (NGS). | |
Parameters Evaluated with RapidNIPTPlus
Autosomal Aneuploidies
| Monosomy 1 / Trisomy 1 | Monosomy 12 / Trisomy 12 |
| Monosomy 2 / Trisomy 2 | Monosomy 13 / Trisomy 13 (Patau Syndrome) |
| Monosomy 3 / Trisomy 3 | Monosomy 14 / Trisomy 14 |
| Monosomy 4 / Trisomy 4 | Monosomy 15 / Trisomy 15 |
| Monosomy 5 / Trisomy 5 | Monosomy 16 / Trisomy 16 |
| Monosomy 6 / Trisomy 6 | Monosomy 17 / Trisomy 17 |
| Monosomy 7 / Trisomy 7 | Monosomy 18 / Trisomy 18 (Edwards Syndrome) |
| Monosomy 8 / Trisomy 8 | Monosomy 19 / Trisomy 19 |
| Monosomy 9 / Trisomy 9 | Monosomy 20 / Trisomy 20 |
| Monosomy 10 / Trisomy 10 | Monosomy 21 / Trisomy 21 (Down Syndrome) |
| Monosomy 11 / Trisomy 11 | Monosomy 22 / Trisomy 22 |
Sex Chromosome Aneuploidies
| Deletion / Duplication Syndromes Evaluated with RapidNIPTPlus | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| 22q11.2 deletion (DiGeorge syndrome) (for 3–10 Mb) |
| Condition | Sensitivity (%) |
|---|---|
| Trisomy 21 | 99.17% |
| Trisomy 18 | 98.24% |
| Trisomy 13 | >99.9 |
| Rare autosomal aneuploidies | NA |
| Deletion/Duplication >10Mb | 88.89% |
| Deletion/Duplication <10Mb | 72.73% |
| Method | |
|---|---|
| RapidNIPTPlus analyzes cfDNA (cell-free DNA) isolated from maternal blood using whole-genome sequencing based on BGI technology, performed on the DNBSEQ-G400 platform in compliance with the CE-IVD protocol. | |
